Gabather AB (publ) (STO:GABA)

Sweden · Delayed Price · Currency is SEK

0.0358

-0.0006 (-1.65%)

Apr 29, 2026, 4:19 PM CET

-9.60% (1Y)

Market Cap	17.90M
Revenue (ttm)	n/a
Net Income (ttm)	-4.65M
Shares Out	491.63M
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,078,361
Average Volume	6,346,823
Open	0.0344
Previous Close	0.0364
Day's Range	0.0334 - 0.0386
52-Week Range	0.0230 - 0.1300
Beta	-0.65
RSI	45.45
Earnings Date	May 29, 2026

About Gabather AB

Gabather AB (publ), a pharmaceutical company, develops drug candidates for the treatment of central nervous system diseases. The company offers drugs primarily in the areas of anti-psychotics, anti-depressants and anxiolytics, and analgesics, as well as cognition-enhancing treatments, including Alzheimer’s disease. It focuses on developing GT-002, a pro-cognitive drug candidate for the treatment of Alzheimer’s disease, schizophrenia, and major depressive disorders. The company was incorporated in 2014 and is based in Södertälje, Sweden. [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2014

Employees 3

Stock Exchange Nasdaq Stockholm

Ticker Symbol GABA

Full Company Profile

Financial Performance

Financial Statements

News

Gabather AB Transcript: Investor Update

GT002, a novel pro-cognitive GABA modulator, is in phase 2 trials for schizophrenia, with key results expected by mid-2025. A provisional US patent was filed for its unique neural fingerprint, and partnership discussions with major pharma are ongoing, targeting a licensing deal next year.

5 months ago - Transcripts

Gabather AB Transcript: Investor Update

GT002, a selective GABA A modulator, is advancing to phase II trials for cognitive impairment in schizophrenia, with strong safety data and unique biomarker-driven development. Licensing discussions are ongoing, and first patient data is expected by end of Q1 next year.

5 months ago - Transcripts

Gabather AB Transcript: Investor Update

A fully funded Phase II trial for GT-002 in schizophrenia is set to start in Q1, with preliminary data expected in Q3. The company is targeting a licensing deal by Q4 2025, supported by a strong safety profile and broad market potential for its lead candidate.

1 year ago - Transcripts